EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Ghrelin and relamorelin counteract hypoglycemia in mice engrafted with congenital hyperinsulinism stem cell-derived islets

Väinö Lithovius iD, Hossam Montaser, Jonna Saarimäki-Vire, Hazem Ibrahim, Tom Barsby, Diego Balboa, Timo Otonkoski

Stem Cells Translational Medicine · 20.07.2026 · 15 (8)

DOI: 10.1093/stcltm/szag055 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Stem Cells Translational Medicine, online erschienen am 05.08.2026. Verfasst von Väinö Lithovius und 6 weiteren Autor:innen. Beteiligte Einrichtung: Stem Cells and Metabolism Research Program of the Faculty of Medicine, University of Helsinki, Helsinki, 00290, Finland. Hauptthemen laut MEDLINE: Congenital Hyperinsulinism, Ghrelin, Islets of Langerhans, Hypoglycemia. Die Arbeit nennt 69 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Academy of Finland, Center of Excellence "Metastem", Novo Nordisk Foundation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

KATP-channel-related hyperinsulinism (KATPHI) is a rare genetic disorder of the pancreatic beta cells, manifesting as life-threatening hypoglycemia in neonates due to excessive insulin secretion. Management of the severe diffuse form of KATPHI currently lacks treatment options, as the first-line therapy octreotide is often insufficiently effective, necessitating radical pancreatectomy in many patients.

Methods

In this study, we differentiated stem cells carrying the KATPHI-causing mutation KCNJ11-/- to stem cell-derived islets (SC-islets) to develop new pharmaceutical therapies for KATPHI. We tested seven candidate molecules in vitro and the most effective ones in vivo in immunocompromised mice that were transplanted with the human KCNJ11-/- SC-islets.

Results

KCNJ11 -/- SC-islets inappropriately secreted 3.9 times more insulin in low glucose than KCNJ11+/+ controls. Transplanted KCNJ11-/- SC-islets caused persistent hyperinsulinemia and hypoglycemia to the recipient mice. We tested acyl-ghrelin identified in our in vitro experiments and its long-acting analogue relamorelin in these mice. Acyl-ghrelin and relamorelin alone increased fasting blood glucose. Combining relamorelin with octreotide increased blood glucose synergistically, ie, more than the sum of each drug alone, reverting hypoglycemia to normoglycemia while reducing the excessive insulin secretion.

Conclusions

We show that ghrelin-receptor agonists have acute anti-hypoglycemic effects in a humanized mouse model of KATPHI, especially when combined with octreotide. Relamorelin has been tested in >650 diabetic adults with little side effects, leading us to propose relamorelin–octreotide combination for further development as a therapeutic candidate for severe KATPHI patients.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Congenital HyperinsulinismGhrelinIslets of LangerhansHypoglycemiaIslets of Langerhans TransplantationStem CellsAnimalsMiceHumansKcnj11 ChannelPotassium Channels, Inwardly RectifyingOctreotide

Stichwörter der Autor:innen

congenital hyperinsulinismdisease modelingghrelinhypoglycemiastem cell-derived islets

Substanzen

GhrelinKcnj11 ChannelPotassium Channels, Inwardly RectifyingOctreotide

Autor:innen und Institutionen

  • Stem Cells and Metabolism Research Program of the Faculty of Medicine, University of Helsinki, Helsinki, 00290, Finland.
  • Children's Hospital, Helsinki University Hospital, Helsinki, 00290, Finland.

ORCID-Profile: Väinö Lithovius

Förderung

  • Academy of Finland
  • Center of Excellence "Metastem"
  • Novo Nordisk Foundation
  • Center of Excellence “Metastem”

Zitieren

APA

Lithovius, V., Montaser, H., Saarimäki-Vire, J., Ibrahim, H., Barsby, T., Balboa, D., & Otonkoski, T. (2026). Ghrelin and relamorelin counteract hypoglycemia in mice engrafted with congenital hyperinsulinism stem cell-derived islets. Stem Cells Translational Medicine, 15(8). https://doi.org/10.1093/stcltm/szag055

Vancouver

Lithovius V, Montaser H, Saarimäki-Vire J, Ibrahim H, Barsby T, Balboa D, et al. Ghrelin and relamorelin counteract hypoglycemia in mice engrafted with congenital hyperinsulinism stem cell-derived islets. Stem Cells Translational Medicine. 2026;15(8). doi:10.1093/stcltm/szag055

BibTeX
@article{Lithovius2026,
  author = {Lithovius, Väinö and Montaser, Hossam and Saarimäki-Vire, Jonna and Ibrahim, Hazem and Barsby, Tom and Balboa, Diego and Otonkoski, Timo},
  title = {Ghrelin and relamorelin counteract hypoglycemia in mice engrafted with congenital hyperinsulinism stem cell-derived islets},
  journal = {Stem Cells Translational Medicine},
  year = {2026},
  volume = {15},
  number = {8},
  doi = {10.1093/stcltm/szag055}
}
Kostenlos starten →